Discovery of novel serine/threonine protein phosphatase 1 inhibitors from traditional Chinese medicine through virtual screening and biological assays

References

• Cannon, J. F. (2013). How phosphorylation activates the protein phosphatase-1 • inhibitor-2 complex. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834(1), 71–86. doi:10.1016/j.bbapap.2012.09.003
   PubMed Web of Science ®Google Scholar
• Carrara, M., Sigurdardottir, A., & Bertolotti, A. (2017). Decoding the selectivity of eIF2α holophosphatases and PPP1R15A inhibitors. Nature Structural & Molecular Biology, 24(9), 708–716. doi:10.1038/nsmb.3443
   PubMed Web of Science ®Google Scholar
• Case, D., Betz, R., Cerutti, D. S., Cheatham, T., Darden, T., Duke, R., … Kollman, P. A. (2016). Amber 2016. San Francisco, CA: University of California, San Francisco.
   Google Scholar
• Chen, G., Zhou, X., Florea, S., Qian, J., Cai, W., Zhang, Z., … Kranias, E. G. (2010). Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Research in Cardiology, 105(5), 573–581. doi:10.1007/s00395-010-0106-3
   PubMed Web of Science ®Google Scholar
• Chen, K.-C., Chen, H.-Y., & Chen, C. Y.-C. (2014). Potential protein phosphatase 2A agents from traditional Chinese medicine against cancer. Evidence-Based Complementary and Alternative Medicine, 2014, 436863. doi:10.1155/2014/436863
   PubMed Web of Science ®Google Scholar
• Chen, Y., de Bruyn Kops, C., & Kirchmair, J. (2017). Data resources for the computer-guided discovery of bioactive natural products. Journal of Chemical Information and Modeling, 57(9), 2099–2111. doi:10.1021/acs.jcim.7b00341
   PubMed Web of Science ®Google Scholar
• Choy, M. S., Swingle, M., D’Arcy, B., Abney, K., Rusin, S. F., Kettenbach, A. N., … Peti, W. (2017). PP1:tautomycetin complex reveals a path toward the development of PP1-specific inhibitors. Journal of the American Chemical Society, 139(49), 17703–17706. doi:10.1021/jacs.7b09368
   PubMed Web of Science ®Google Scholar
• Chung, V., Mansfield, A. S., Braiteh, F., Richards, D., Durivage, H., Ungerleider, R. S., … Kovach, J. S. (2017). Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: An open-label, dose escalation, first-in-human, phase I trial. Clinical Cancer Research, 23(13), 3277–3284. doi:10.1158/1078-0432.CCR-16-2299
   PubMed Web of Science ®Google Scholar
• De Munter, S., Kohn, M., & Bollen, M. (2013). Challenges and opportunities in the development of protein phosphatase-directed therapeutics. ACS Chemical Biology, 8(1), 36–45. doi:10.1021/cb300597g
   PubMed Web of Science ®Google Scholar
• Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009). Protein phosphatase 2A regulatory subunits and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1795(1), 1–15. doi:10.1016/j.bbcan.2008.05.005
   PubMed Web of Science ®Google Scholar
• El-Hasab, M. A. E., El-Bastawissy, E. E., & El-Moselhy, T. F. (2018). Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation. Journal of Biomolecular Structure and Dynamics, 36(7), 1713–1727. doi:10.1080/07391102.2017.1332689
   PubMed Web of Science ®Google Scholar
• Ferreira, M., Beullens, M., Bollen, M., & Van Eynde, A. (2018). Functions and therapeutic potential of protein phosphatase 1: Insights from mouse genetics. BBA - Molecular Cell Research, 1866, 16–30. doi:10.1016/j.bbamcr.2018.07.019
   PubMed Web of Science ®Google Scholar
• Fontanillo, M., & Kohn, M. (2018). Microcystins: Synthesis and structure-activity relationship studies toward PP1 and PP2A. Bioorganic & Medicinal Chemistry, 26(6), 1118–1126. doi:10.1016/j.bmc.2017.08.040
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., … Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. doi:10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Fujiki, H., Suganuma, M., Yoshizawa, S., Nishiwaki, S., Winyar, B., & Sugimura, T. (1991). Mechanisms of action of okadaic acid class tumor promoters on mouse skin. Environmental Health Perspectives, 93, 211–214. doi:10.1289/ehp.9193211
   PubMed Web of Science ®Google Scholar
• Goldberg, J., Huang, H. B., Kwon, Y. G., Greengard, P., Nairn, A. C., & Kuriyan, J. (1995). Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature, 376(6543), 745–753. doi:10.1038/376745a0
   PubMed Web of Science ®Google Scholar
• Gupta, S., Jadaun, A., Kumar, H., Raj, U., Varadwaj, P. K., & Rao, A. R. (2015). Exploration of new drug-like inhibitors for serine/threonine protein phosphatase 5 of Plasmodium falciparum: A docking and simulation study. Journal of Biomolecular Structure and Dynamics, 33(11), 2421–2441. doi:10.1080/07391102.2015.1051114
   PubMed Web of Science ®Google Scholar
• Heijman, J., Ghezelbash, S., Wehrens, X. H. T., & Dobrev, D. (2017). Serine/Threonine Phosphatases in atrial fibrillation. Journal of Molecular and Cellular Cardiology, 103, 110–120. doi:10.1016/j.yjmcc.2016.12.009
   PubMed Web of Science ®Google Scholar
• Heroes, E., Lesage, B., Gornemann, J., Beullens, M., Van Meervelt, L., & Bollen, M. (2013). The PP1 binding code: A molecular-lego strategy that governs specificity. FEBS Journal, 280(2), 584–595. doi:10.1111/j.1742-4658.2012.08547.x
   PubMed Web of Science ®Google Scholar
• Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., & Simmerling, C. (2006). Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins: Structure, Function, and Bioinformatics, 65(3), 712–725. doi:10.1002/prot.21123
   PubMed Web of Science ®Google Scholar
• Hou, X., Rooklin, D. W., Yang, D., Liang, X., Li, K., Lu, J., … Fang, H. (2018). Computational strategy for bound state structure prediction in structure-based virtual screening: A case study of protein tyrosine phosphatase receptor type O inhibitors. Journal of Chemical Information and Modeling, 58, 2331–2342. doi:10.1021/acs.jcim.8b00548
   PubMed Web of Science ®Google Scholar
• Hsu, L. C., Huang, X., Seasholtz, S., Potter, D. M., & Gollin, S. M. (2006). Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines. Oncogene, 25(40), 5517–5526. doi:10.1038/sj.onc.1209563
   PubMed Web of Science ®Google Scholar
• Ishikawa, K., Fish, K. M., Tilemann, L., Rapti, K., Aguero, J., Santos-Gallego, C. G., … Hajjar, R. J. (2014). Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Molecular Therapy, 22(12), 2038–2045. doi:10.1038/mt.2014.127
   PubMed Web of Science ®Google Scholar
• Kelker, M. S., Page, R., & Peti, W. (2009). Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: A novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors. Journal of Molecular Biology, 385(1), 11–21. doi:10.1016/j.jmb.2008.10.053
   PubMed Web of Science ®Google Scholar
• Kita, A., Matsunaga, S., Takai, A., Kataiwa, H., Wakimoto, T., Fusetani, N., … Miki, K. (2002). Crystal structure of the complex between calyculin A and the catalytic subunit protein phosphatase 1. Structure, 10(8), 71149. doi:10.1016/S0969-2126(02)00764-5
   Web of Science ®Google Scholar
• Kuzmanic, A., & Zagrovic, B. (2010). Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors. Biophysical Journal, 98(5), 861–871. doi:10.1016/j.bpj.2009.11.011
   PubMed Web of Science ®Google Scholar
• Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007). BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Research, 35(Database issue), 198–201.
   PubMed Web of Science ®Google Scholar
• Lu, S.-H., Wu, J. W., Liu, H.-L., Zhao, J.-H., Liu, K.-T., Chuang, C.-K., … Ho, Y. (2011). The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies. Journal of Biomedical Science, 18(1), 8.doi:10.1186/1423-0127-18-8
   PubMed Web of Science ®Google Scholar
• Mathe, C., Beyer, D., M-Hamvas, M., & Vasas, G. (2016). The effects of microcystins (Cyanobacterial Heptapeptides) on the eukaryotic cytoskeletal system. Mini-Reviews in Medicinal Chemistry, 16(13), 1063–1077. doi:10.2174/1389557516666160219130732
   PubMed Web of Science ®Google Scholar
• Matsoukas, M.-T., Aranguren-Ibáñez, Á., Lozano, T., Nunes, V., Lasarte, J. J., Pardo, L., & Pérez-Riba, M. (2015). Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners. Science Signaling, 8(382), ra63–11. doi:10.1126/scisignal.2005918
   PubMed Web of Science ®Google Scholar
• Maynes, J. T., Luu, H. A., Cherney, M. M., Andersen, R. J., Williams, D., Holmes, C. F., & James, M. N. (2006). Crystal structures of protein phosphatase-1 bound to motuporin and dihydromicrocystin-LA: Elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins. Journal of Molecular Biology, 356(1), 111–120. doi:10.1016/j.jmb.2005.11.019
   PubMed Web of Science ®Google Scholar
• Medina, M., Avila, J., & Villanueva, N. (2013). Use of okadaic acid to identify relevant phosphoepitopes in pathology: A focus on neurodegeneration. Marine Drugs, 11(5), 1656–1668. doi:10.3390/md11051656
   PubMed Web of Science ®Google Scholar
• Meyer-Roxlau, S., Lämmle, S., Opitz, A., Künzel, S., Joos, J. P., Neef, S., … El-Armouche, A. (2017). Differential regulation of protein phosphatase 1 (PP1) isoforms in human heart failure and atrial fibrillation. Basic Research in Cardiology, 112(4), 43.doi:10.1007/s00395-017-0635-0
   PubMed Web of Science ®Google Scholar
• Onufriev, A., Bashford, D., & Case, D. A. (2004). Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins: Structure, Function, and Bioinformatics, 55(2), 383–394. doi:10.1002/prot.20033
   PubMed Web of Science ®Google Scholar
• Park, H., Lee, H. S., Ku, B., Kim, S. J., & Lee, S.-R. (2017). Two-track virtual screening approach to identify both competitive and allosteric inhibitors of human small C-terminal domain phosphatase 1. Journal of Computer-Aided Molecular Design, 31(8), 743–753. doi:10.1007/s10822-017-0037-2
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham, T. E. (2013). PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. Journal of Chemical Theory and Computation, 9(7), 3084.doi:10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Rogers, J. P., Beuscher, A. E., Flajolet, M., McAvoy, T., Nairn, A. C., Olson, A. J., & Greengard, P. (2006). Discovery of protein phosphatase 2C inhibitors by virtual screening. Journal of Medicinal Chemistry, 49(5), 1658–1667. doi:10.1021/jm051033y
   PubMed Web of Science ®Google Scholar
• Ruhlmann, A., & Nordheim, A. (1997). Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. Immunobiology, 198(1–3), 192–206. doi:10.1016/S0171-2985(97)80040-X
   PubMed Web of Science ®Google Scholar
• Ryckaert, J. P., Ciccotti, G., & Berendsen, H. J. C. (1977). Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n -alkanes. Journal of Computational Physics, 23(3), 327–341. doi:10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Sanderson, K. (2011). Databases aim to bridge the East-West divide of drug discovery. Nature Medicine, 17(12), 1531. doi:10.1038/nm1211-1531a
   PubMed Web of Science ®Google Scholar
• Sequeira, V., & Maack, C. (2018). Rebalancing protein phosphorylation in heart failure to prevent arrhythmias. European Journal of Heart Failure, 20(12), 1686–1689. doi:10.1002/ejhf.1315
   PubMed Web of Science ®Google Scholar
• Shi, Y. (2009). Serine/threonine phosphatases: Mechanism through structure. Cell, 139(3), 468–484. doi:10.1016/j.cell.2009.10.006
   PubMed Web of Science ®Google Scholar
• Sierecki, E., Sinko, W., McCammon, J. A., & Newton, A. C. (2010). Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening. Journal of Medicinal Chemistry, 53(19), 6899–6911. doi:10.1021/jm100331d
   PubMed Web of Science ®Google Scholar
• Su, X.-Z., & Miller, L. H. (2015). The discovery of artemisinin and the Nobel Prize in Physiology or Medicine. Science China Life Sciences, 58(11), 1175–1179. doi:10.1007/s11427-015-4948-7
   PubMed Web of Science ®Google Scholar
• Sydnes, M. O., & Isobe, M. (2010). Tautomycin's interactions with protein phosphatase 1. Chemistry - An Asian Journal, 5(3), 410–420. doi:10.1002/asia.200900394
   PubMed Web of Science ®Google Scholar
• Theurillat, J.-P., Metzler, S. C., Henzi, N., Djouder, N., Helbling, M., Zimmermann, A.-K., … Krek, W. (2011). URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell, 19(3), 317–332. doi:10.1016/j.ccr.2011.01.019
   PubMed Web of Science ®Google Scholar
• Twiner, M. J., Doucette, G. J., Pang, Y., Fang, C., Forsyth, C. J., & Miles, C. O. (2016). Structure-activity relationship studies using natural and synthetic okadaic acid/dinophysistoxin toxins. Marine Drugs, 14(11), 207–207/212. doi:10.3390/md14110207
   Web of Science ®Google Scholar
• Volter, K. E., Embrey, K. J., Pierens, G. K., & Quinn, R. J. (2001). A study of the binding requirements of calyculin A and dephosphonocalyculin A with PP1, development of a molecular recognition model for the binding interactions of the okadaic acid class of compounds with PP1. European Journal of Pharmaceutical Sciences, 12(3), 181–194. doi:10.1016/S0928-0987(00)00116-0
   PubMed Web of Science ®Google Scholar
• Wakimoto, T., Egami, Y., & Abe, I. (2016). Calyculin: Nature's way of making the sponge-derived cytotoxin. Natural Product Reports, 33(6), 751–760. doi:10.1039/C5NP00123D
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157.doi:10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Wang, L., & Yan, F. (2017). Deprotonation states of the two active site water molecules regulate the binding of protein phosphatase 5 with its substrate: A molecular dynamics study. Protein Science, 26(10), 2010–2020. doi:10.1002/pro.3239
   PubMed Web of Science ®Google Scholar
• Watanabe, S., Ishikawa, K., Fish, K., Oh, J. G., Motloch, L. J., Kohlbrenner, E., … Hajjar, R. J. (2017). Protein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failure. Journal of the American College of Cardiology, 70(14), 1744–1756. doi:10.1016/j.jacc.2017.08.013
   PubMed Web of Science ®Google Scholar